Bryan K Kee, M.D.

Peer-Reviewed Articles

1. Morris VK, Parseghian CM, Bahrambeigi V, Abdelfattah N, Xiao L, Agrawal A, Lin K, Raghav KPS, Wolff RA, Dasari A, Huey RW, Kee BK, Overman MJ, Willis JA, Le PH, Escano M, Baig YC, Pan K, Menter D, Tam AL, Foo WC, Shen L, Lee HM, Gallup TD, Margain C, Gallup D, Rajapakshe KI, Guerrero PA, Wang J, Corcoran RB, Maitra A, Yun K, Kopetz S. Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF(V600E) metastatic colorectal cancer. Cancer Cell, 2025. e-Pub 2025. PMID: 40882637.
2. Pellatt AJ, Bent A, Hornstein N, Parseghian C, Huey R, Raghav K, Morris V, Overman M, Morelli P, Willis J, Le P, Shen JP, Kee B, Eluri M, Higbie V, Alfaro-Munoz K, Aziz K, Kell R, Sun R, Kopetz S, Dasari A. Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT. JCO Precis Oncol 9:e2500142, 2025. e-Pub 2025. PMID: 40669021.
3. Pattalachinti VK, Haque E, Yousef M, Yousef A, Chowdhury S, Overman M, Parseghian CM, Morris VK, Kee B, Huey RW, Raghav K, Court CM, Shen JP. BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy. NPJ Precis Oncol 9(1):38, 2025. e-Pub 2025. PMID: 39910160.
4. White MG, Zeineddine MA, Fallon EA, Zeineddine FA, Dansby J, Chowdhury S, Hornstein N, Yousef A, Yousef M, Bhutiani N, Gu Y, Kee B, Dasari A, Overman MJ, Raghav K, Kopetz S, Uppal A, Taggart M, Newhook T, Fournier K, Helmink B, Drusbosky LM, Shen JP. The Landscape of ctDNA in Appendiceal Adenocarcinoma. Clin Cancer Res 31(3):551-560, 2025. e-Pub 2025. PMID: 39679931.
5. Yousef M, Yousef A, Chowdhury S, Fanaeian MM, Knafl M, Peterson J, Zeineddine M, Alfaro K, Zeineddine F, Goldstein D, Hornstein N, Dasari A, Huey R, Johnson B, Higbie V, Bent A, Kee B, Lee M, Morelli MP, Morris VK, Halperin D, Overman MJ, Parseghian C, Vilar E, Wolff R, Raghav KP, White MG, Uppal A, Sun R, Wang W, Kopetz S, Willis J, Shen JP. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival. JAMA Oncol 10(11), 2024. e-Pub 2024. PMID: 39264607.
6. Chang, E, Wong, FC, Chasen, B, Erwin, WD, Das, P, Holliday, EB, Koong, A, Ludmir, EB, Minsky, B, Noticewala, SS, Smith, GL, Taniguchi, C, Rodriguez, MJ, Beddar, S, Martin, RM, Niedzielski, JS, Sawakuchi, GO, Schueler, E, Perles, LA, Xiao, L, Szklaruk, J, Park, PC, Dasari, NV, Kaseb, A, Kee, BK, Lee, SS, Overman, MJ, Willis, JA, Wolff, RA, Tzeng, CD, Vauthey, JN, Koay, EJ. Phase i trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume. JNCI Cancer Spectrum 8(3), 2024. e-Pub 2024. PMID: 38730548.
7. Yousef A, Yousef M, Zeineddine MA, More A, Fanaeian M, Chowdhury S, Knafl M, Edelkamp P, Ito I, Gu Y, Pattalachinti V, Naini ZA, Zeineddine FA, Peterson J, Alfaro K, Foo WC, Jin J, Bhutiani N, Higbie V, Scally CP, Kee B, Kopetz S, Goldstein D, Strach M, Williamson A, Aziz O, Barriuso J, Uppal A, White MG, Helmink B, Fournier KF, Raghav KP, Taggart MW, Overman MJ, Shen JP. Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma. JAMA Netw Open 7(2):e240260, 2024. e-Pub 2024. PMID: 38416491.
8. Higbie, V, Shah, P, Bent, AH, Dasari, NV, Huey, RW, Johnson, B, Kee, BK, Kopetz, S, Lee, MS, Ludford, K, Morelli, MP, Morris, VK, Parseghian, C, Raghav, KS, Shen, JY, Willis, JA, Wolff, RA, Overman, MJ. Natural history and patterns of progression for dMMR/MSI-H colorectal cancer treated with immune checkpoint blockade. Journal of Clinical Oncology 42(3), 2024. e-Pub 2024.
9. Simmons K, Thomas JV, Ludford K, Willis JA, Higbie VS, Raghav KPS, Johnson B, Dasari A, Kee BK, Parseghian CM, Lee MS, Le PH, Morelli MP, Shen JP, Bent A, Vilar E, Wolff RA, Kopetz S, Overman MJ, Morris VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun 3(12):2510-2517, 2023. e-Pub 2023. PMID: 38085001.
10. Yousef A, Yousef M, Zeineddine M, More A, Chowdhury S, Knafl M, Edelkamp P, Ito I, Gu Y, Pattalachinti V, Naini ZA, Zeineddine F, Peterson J, Alfaro K, Foo WC, Jin J, Bhutiani N, Higbie V, Scally C, Kee B, Kopetz S, Goldstein D, Uppal A, White MG, Helmink B, Fournier K, Raghav K, Taggart M, Overman MJ, Shen JP. The Clinical Significance of CEA, CA19-9, and CA125 in Management of Appendiceal Adenocarcinoma. medRxiv, 2023. e-Pub 2023. PMID: 37745596.
11. Napolitano S, Parikh AR, Henry J, Parseghian CM, Willis J, Raghav KP, Morris VK, Johnson B, Kee BK, Dasari AN, Overman MJ, Luthra R, Drusbosky LM, Corcoran RB, Kopetz S, Sun R. Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precis Oncol 7:e2300228, 2023. e-Pub 2023. PMID: 37824798.
12. Piha-Paul SA, Tseng C, Tran HT, Gao M, Karp DD, Subbiah V, Tsimberidou AM, Kawedia JD, Fu S, Pant S, Yap TA, Morris VK, Kee BK, Blum Murphy M, Lim J, Meric-Bernstam F. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol 92(2):107-118, 2023. e-Pub 2023. PMID: 37314501.
13. Tsimberidou AM, Guenther K, Andersson BS, Mendrzyk R, Alpert A, Wagner C, Nowak A, Aslan K, Satelli A, Richter F, Kuttruff-Coqui S, Schoor O, Fritsche J, Coughlin Z, Mohamed AS, Sieger K, Norris B, Ort R, Beck J, Vo HH, Hoffgaard F, Ruh M, Backert L, Wistuba II, Fuhrmann D, Ibrahim NK, Morris VK, Kee BK, Halperin DM, Nogueras-Gonzalez GM, Kebriaei P, Shpall EJ, Vining D, Hwu P, Singh H, Reinhardt C, Britten CM, Hilf N, Weinschenk T, Maurer D, Walter S. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer. Cancer Immunol Res 11(7):925-945, 2023. e-Pub 2023. PMID: 37172100.
14. Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, Huey RW, Johnson B, Kee B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian C, Raghav K, Willis J, Wolff RA, Kawaguchi Y, Vauthey JN, Sun R, Kopetz S, Shen JP. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol 7(1):16, 2023. e-Pub 2023. PMID: 36781990.
15. Davis JS, Chavez JC, Kok M, San Miguel Y, Lee HY, Henderson H, Overman MJ, Morris V, Kee B, Fogelman D, Advani SM, Johnson B, Parseghian C, Shen JP, Dasari A, Shaw KR, Vilar E, Raghav KP, Shureiqi I, Wolff RA, Meric-Bernstam F, Maru D, Menter DG, Kopetz S, Chang S. Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open 5(10):e2236357, 2022. e-Pub 2022. PMID: 36239938.
16. Morris VK, Overman MJ, Lam M, Parseghian CM, Johnson B, Dasari A, Raghav K, Kee BK, Huey R, Wolff RA, Shen JP, Li J, Zorrilla I, Tzeng CD, Tran Cao HS, Chun YS, Newhook TE, Vauthey N, Duose D, Luthra R, Haymaker C, Kopetz S. Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
17. Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJ. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer 10(8), 2022. e-Pub 2022. PMID: 36007963.
18. Rogers JE, Woodard TL, Gonzalez GM, Dasari A, Johnson B, Morris VK, Kee B, Vilar E, Nancy You Y, Chang GJ, Bednarski B, Skibber JM, Rodriguez-Bigas MA, Eng C. Colorectal cancer during pregnancy or postpartum: Case series and literature review. Obstet Med 15(2):118-124, 2022. e-Pub 2022. PMID: 35845232.
19. Morris V, Kee B, Overman M, Dasari A, Raghav K, Johnson B, Parseghian C, Wolff RA, Garg N, Eng C, Kopetz S. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol 13(2):647-656, 2022. e-Pub 2022. PMID: 35557581.
20. Morris, VK, Overman, MJ, Lam, MC, Parseghian, C, Johnson, B, Dasari, NV, Raghav, KS, Kee, BK, Huey, RW, Wolff, RA, Shen, JY, Li, J, Zorrilla, I, Tzeng, CD, Tran Cao, HS, Chun, YS, Newhook, TE, Vauthey, JN, Duose, D, Luthra, R, Haymaker, CL, Kopetz, S. Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer. Cancer Research Communications 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
21. Rogers JE, Woodard TL, Dasari A, Kee B, Das P, Bednarski BK, Skibber JM, Rodriguez-Bigas MA, Eng C. Fertility discussions in young adult stage III colorectal cancer population: a single-center institution experience. Support Care Cancer 29(12):7351-7354, 2021. e-Pub 2021. PMID: 34050401.
22. Dumbrava EE, Call SG, Huang HJ, Stuckett AL, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder SL, Koenig KH, Barcenas CH, Kee BK, Fogelman DR, Kopetz ES, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open 6(5):100230, 2021. e-Pub 2021. PMID: 34479035.
23. Kanikarla Marie P, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, Foo WC, Maru DM, Chun YS, Futreal A, Kee B, Menter D, Solis L, Tzeng CW, Parseghian C, Raghav K, Morris V, Chang CC, Jenq R, Tam A, Bernatchez C, Kopetz S, Vauthey JN, Overman MJ. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res 27(11):3039-3049, 2021. e-Pub 2021. PMID: 33811152.
24. Advani SM, Swartz MD, Loree J, Davis JS, Sarsashek AM, Lam M, Lee MS, Bressler J, Lopez DS, Daniel CR, Morris V, Shureqi I, Kee B, Dasari A, Vilar E, Overman M, Hamilton S, Maru D, Braithwaite D, Kopetz S. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clin Colorectal Cancer 20(2):137-147.e1, 2021. e-Pub 2021. PMID: 33229221.
25. Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian C, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer. JCO Precis Oncol 5:613-621, 2021. e-Pub 2021. PMID: 34250391.
26. Jácome AA, Kee B, Fogelman D, Dasari A, Shureiqi I, Raghav K, Morris V, Johnson B, Overman M, Wolff R, Kopetz S, Rogers J, Ahmed SU, Mehdizadeh A, Rothschild N, Eng C. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer 19(4):248-255.e6, 2020. e-Pub 2020. PMID: 32665092.
27. Jácome AA, Ohinata A, Mahvash A, Overman MJ, Kee B, Fogelman D, Morris VK, Johnson B, Rothschild ND, Wolff RA, Eng C. Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clin Colorectal Cancer 19(4):e189-e199, 2020. e-Pub 2020. PMID: 32680816.
28. Advani SM, Shi Q, Overman MJ, Loree JM, Lam M, Morris V, Shureiqi I, Kee B, Dasari A, Vilar E, Sarshekeh AM, Lin HK, Manuel S, Hamilton S, Raghav K, Maru D, Kopetz S, Wang XS. Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer 19(1):48-56.e2, 2020. e-Pub 2020. PMID: 32008976.
29. Korphaisarn K, Morris V, Davis JS, Overman MJ, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Trupti M, Wolff RA, Eng C, Menter DG, Hamilton S, Kopetz S. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer, 2019. e-Pub 2019. PMID: 31406299.
30. Johnson B, Loree JM, Jacome AA, Mendis S, Syed M, Morris Ii VK, Parseghian CM, Dasari A, Pant S, Raymond VM, Vilar E, Overman M, Kee B, Eng C, Raghav K, Kopetz S. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precis Oncol, 2019. e-Pub 2019. PMID: 32914034.
31. Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-challenge. Ann Oncol. e-Pub 2018. PMID: 30462160.
32. Brusco LL, Wathoo C, Mills Shaw KR, Holla VR, Bailey AM, Johnson AM, Khotskaya YB, Litzenburger BC, Sanchez NS, Zeng J, Bernstam EV, Eng C, Kee BK, Amaria RN, Routbort MJ, Mills GB, Mendelsohn J, Meric-Bernstam F. Physician interpretation of genomic test results and treatment selection. Cancer 124(5):966-972, 2018. e-Pub 2018. PMID: 29165790.
33. Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic R, Azad N, Kopetz S. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 29(1):139-144, 2018. e-Pub 2018. PMID: 29069279.
34. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget 8(24):39268-39279, 2017. e-Pub 2017. PMID: 28424412.
35. Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner RG, Naing A, Hong DS, Karp DD, Cabrilo G, Kopetz ES, Subbiah V, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Ann Oncol 28(3):642-650, 2017. e-Pub 2017. PMID: 27993791.
36. Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One 12(3):e0173345, 2017. e-Pub 2017. PMID: 28267766.
37. Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol 2017, 2017. e-Pub 2017. PMID: 29082359.
38. Pereira AAL, Morelli MP, Overman M, Kee B, Fogelman D, Vilar E, Shureiqi I, Raghav K, Eng C, Manuel S, Crosby S, Wolff RA, Banks K, Lanman R, Talasaz A, Kopetz S, Morris V. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One 12(8):e0183949, 2017. e-Pub 2017. PMID: 28850629.
39. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov 6(12):1352-1365, 2016. e-Pub 2016. PMID: 27729313.
40. Overman MJ, Morris V, Moinova H, Manyam G, Ensor J, Lee MS, Eng C, Kee B, Fogelman D, Shroff RT, LaFramboise T, Mazard T, Feng T, Hamilton S, Broom B, Lutterbaugh J, Issa JP, Markowitz SD, Kopetz S. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget 7(41):67495-67506, 2016. e-Pub 2016. PMID: 27542211.
41. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther 15(6):1397-404, 2016. e-Pub 2016. PMID: 27207774.
42. Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol 27(6):1068-74, 2016. e-Pub 2016. PMID: 27045102.
43. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6(27):24581, 2015. e-Pub 2015. PMID: 26405159.
44. Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs 33(4):911-20, 2015. e-Pub 2015. PMID: 25990659.
45. Al-Shamsi HO, Kee BK, Tetzlaff MT, Wolff RA. Capecitabine-induced leukocytoclastic vasculitis under neoadjuvant chemotherapy for locally advanced colorectal cancer. J Gastrointest Oncol 6(3):E40-3, 2015. e-Pub 2015. PMID: 26029464.
46. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6(14):12809-21, 2015. e-Pub 2015. PMID: 25980577.
47. Morelli MP, Overman MJ, Dasari A, Kazmi SMA, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26(4):731-736, 2015. e-Pub 2015. PMID: 25628445.
48. Morris V, Overman MJ, Jiang ZQ, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colrectal Cancer 13(3):164-71, 2014. e-Pub 2014. PMID: 25069797.
49. Subbiah IM, Blackmon SH, Correa AM, Kee B, Vaporciyan AA, Swisher SG, Eng C. Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma. Oncotarget 5(16):6584-93, 2014. e-Pub 2014. PMID: 25051371.
50. Kee BK, Morris JS, Slack RS, Crocenzi T, Wong L, Esparaz B, Overman M Glover K, Jones D, Wen S, Fisch MJ. A Phase II randomized bouble blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Support Care Cancer. e-Pub 2014. PMID: 25160493.
51. Tanasanvimon S, Garg N, Viswanathan C, Truong M, Kaur H, Kee BK, Sahin IH, Javle MM, Garrett CR. High prevalence of recurrent thrombosis in subsets of cancer patients with isolated gonadal vein thrombosis: a single center retrospective study. Thromb Res 133(2):154-7, 2014. e-Pub 2014. PMID: 24331209.
52. Sahin IH, Kazmi SM, Yorio JT, Bhadkamkar NA, Kee BK, Garrett CR. Rare though not mutually exclusive: a report of three cases of concomitant KRAS and BRAF mutation and a review of the literature. J Cancer 4(4):320-322, 2013. e-Pub 2013. PMID: 23569465.
53. Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng C. Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. Clin Colorectal Cancer 11(3):191-4, 2012. e-Pub 2012. PMID: 22280844.
54. Garrett CR, Hassabo HM, Bhadkamkar NA, Wen S, Baladandayuthapani V, Kee BK, Eng C, Hassan MM. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer 106(8):1374-8, 2012. e-Pub 2012. PMID: 22421948.
55. Yorio JT, Bhadkamkar NA, Kee BK, Garrett CR. A Primer on the Current State-of-the-Science Neoadjuvant and Adjuvant Therapy for Patients with Locally Advanced Rectal Adenocarcinomas. Int J Surg Oncol 2012:863034, 2012. e-Pub 2012. PMID: 22666572.
56. Arnold SM, Rinehart JJ, Tsakalozou E, Eckardt JR, Fields SZ, Shelton BJ, DeSimone PA, Kee BK, Moscow JA, Leggas M. A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies. Clin Cancer Res 16(2):673-80, 2010. e-Pub 2010. PMID: 20068096.

Abstracts

1. Bhamidipati D, Singh Raghav KP, Morris VK, Kopetz S, Kee BK, Johnson B, Willis J, Dasari A, Morelli MP, Parseghian CM, Lee MS, Le P, YC Shen JP, Ludford K, Overman MJ. Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h/dMMR colorectal cancer receiving immunotherapy. J Clin Oncol 40(16_suppl), 2022. e-Pub 2022.
2. Johnson B, Yang D, Dada HI, Morris VK, Wang X, Dasari A, Singh Raghav KP, Kee BK, YC Shen JP, Huey R, Lee MS, Parseghian CM, Le P, Morelli MP, Willis J, Wolff RA, Drusbosky L, Overman MJ, Kopetz S. RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer. Journal of Clinical Oncology 40(16_suppl), 2022. e-Pub 2022.
3. Parseghian CM, Sanchez EV, Sun R, Eluri M, Morris VK, Johnson B, Morelli MP, Overman MJ, Willis J, Huey R, Singh Raghav KP, Dasari A, Kee BK, Wolff RA, YC Shen JP, Kopetz S. Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer. Journal of Clinical Oncology 40(16_suppl), 2022. e-Pub 2022.
4. Bent AH, Maru DM, Vauthey J, Dasari A, Johnson B, Kee BK, Parseghian CM, Menter D, Overman MJ, Morris VK, Fan P, Koyama K, Maeda N, Kopetz S, Singh Raghav KP. HER3 expression in metastatic colorectal cancer: Defining the clinicomolecular profile of an emerging target. Journal of Clinical Oncology 40(16_suppl), 2022. e-Pub 2022.
5. Simmons K, Kee BK, Singh Raghav KP, Johnson B, Kopetz S, Willis J, Dasari A, Sanchez EV, Ludford K, Parseghian CM, Lee MS, Le P, YC Shen JP, Overman MJ, Morris VK. Clinical outcomes following termination of immunotherapy due to long-term benefit in MSI-H colorectal cancer. J Clin Oncol 40(16_suppl), 2022. e-Pub 2022.
6. Morris VK, Parseghian CM, Escano M, Johnson B, Singh Raghav KP, Dasari A, Huey R, Overman MJ, Willis J, Lee MS, Wolff RA, Kee BK, YC Shen JP, Morelli MP, Tam A, Foo WC, Xiao L, Kopetz S. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. Journal of Clinical Oncology 40(4_suppl):12-12, 2022. e-Pub 2022.
7. Morris V, Lam M, Wang X, Overman M, Johnson B, Kee B, Wolff R, Dasari A, Zorrilla I, Tam A, Maru D, Kopetz S. Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy. J Clin Oncol. e-Pub 2021.
8. Morris V, Raghav K, Dasari A, Overman M, Kee B, Johnson B, Parseghian M, Shen JP, Raymond V, Douse D, Luthra R, Hong D, Janku F, Kopetz S. Utility of circulating tumor DNA in the clinical management of patients with BRAFV600E metastatic colorectal cancer. J Clin Oncol. e-Pub 2021.
9. Johnson B, Thomas J, Dasari A, Raghav K, Sanchez E, Kee B, Eng C, Parseghian C, Morris V, Wolff R, Shureiqi I, Kopetz S, Overman M. A phase II study of durvalumab (MEDI4736) (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Clin Oncol. e-Pub 2020.
10. Morris V, Kee B, Overman M, Fogelman D, Dasari A, Raghav K, Shureiqi I, Johnson B, Parseghian C, Wolff R, Eng C, Garg N, Kopetz S. Clinical and pathologic factors associated with survival in BRAFV600E colorectal cancers. J Clin Oncol. e-Pub 2020.
11. Sarshekeh A, Lam M, Zorrilla I, Holliday E, Das P, Kee B, Overman M, Parseghian C, Shen JP, Tam A, Cuentas E, Zhang L, Wang X, Duose D, Luthra R, Reddy N, Maru D, Kopetz S, Morris V. Consensus molecular subtype (CMS) as a novel integral biomarker in colorectal cancer: A phase II trial of bintrafusp alfa in CMS4 metastatic CRC. J Clin Oncol. e-Pub 2020.
12. Serpas V, Rogers J, Xiao L, Molina-Rudd K, Dasari A, Kee B, Overman M, Johnson B. Impact of antibiotic exposure on the efficacy of immune checkpoint blockade in MSI-H metastatic CRC. J Clin Oncol. e-Pub 2020.
13. Raghav K, Wang X, Xiao L, Dasari A, Morris V, Johnson B, Shen JP, Parseghian C, Kee B, Shureiqi I, Fogelman D, Wolff R, Raymons V, Odegaard J, Lanman R, Overman M, Kopetz S. A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating cell-free tumor DNA (ctDNA) (TACT-D). J Clin Oncol. e-Pub 2020.
14. Singh Raghav KP, Yaeger R, Loree JM, Dasari A, Morris VK, Kee BK, Raymond VM, Nagy RJ, Lanman RB, Strickler JH, Corcoran RB, Overman MJ, Kopetz S, Cancer Center TUOTMA, Houston, TX, Cancer Center MSK, York N, NY, Cancer BC, Vancouver, BC, Canada, Guardant. Comprehensive landscape of gene amplifications (amps) in tissue and circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC). J Clin Oncol 37, 2019. e-Pub 2019.
15. Chung SW, Overman MJ, Morris VK, Fogelman DR, Kee BK, Dasari A, Singh Raghav KP, Shureiqi I, Jiang Z, Jensen-Loewe PA, Wolff RA, Eng C, Menter D, Kopetz S, Davis JS, at Houston UOT, Houston, TX, Cancer Center TUOTMA, Houston, TX, Medical Oncology DOG, Cancer Center TUOTMA, Houston, TX, Medical Oncology DOG, Cancer Center TUOTMA, Houston, TX, Cancer Center UOTMA, Houston, TX, Medical Oncology DOG, Cancer Center TUOTMA, Land S, TX, Center UT, Houston, TX. The association between female hormonal supplementation and molecular types in colorectal cancer. Clin Oncol 37. e-Pub 2019.
16. Frias RL, Lam M, Overman MJ, Morris VK, Fogelman DR, Kee BK, Dasari A, Singh Raghav KP, Shureiqi I, Jiang Z, Jensen-Loewe PA, Wolff RA, Eng C, Menter D, Kopetz S, Davis JS, Medical Oncology DOG, Cancer Center TUOTMA, Houston, TX, Cancer Center TUOTMA, Houston, TX, Medical Oncology DOG, Cancer Center TUOTMA, Houston, TX, Cancer Center UOTMA, Houston, TX, Medical Oncology DOG, Cancer Center TUOTMA, Land S, TX, Center UT, Houston, TX. Meat consumption and BRAF mutation status in colorectal cancer. J Clin Oncol 37, 2019, 2019. e-Pub 2019.
17. Jacome AA, Kee BK, Fogelman DR, Shureiqi I, Dasari A, Singh Raghav KP, Morris VK, Johnson B, Wolff RA, Overman MJ, Kopetz S, Rogers J, Ahmed SU, Mehdizadeh A, Eng C, Center MD, Medical Oncology DOG, Houston, TX, Cancer Center TUOTMA, Houston, TX, Medical Oncology DOG, Cancer Center TUOTMA, Houston, TX, Cancer Center UOTMA, Houston, TX, Medical Oncology DOG, Cancer Center TUOTMA, Houston, TX, Center UT, Houston, TX. FOLFOXIRI versus doublet-regimens in the first-line therapy of MSI-S right-sided (RS) metastatic colorectal cancer (mCRC): A survival analysis. J Clin Oncol 37, 2019. e-Pub 2019.
18. Lima Pereira AA, Loree JM, Davis JS, Lam M, Morris VK, Overman MJ, Singh Raghav KP, Kee BK, Fogelman DR, Sanchez EV, Shureiqi I, Eng C, Manuel S, Crosby S, Wolff RA, Lanman RB, Talasaz A, Janku F, Kopetz S. Predictors for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC). J Clin Oncol 36, 2018. e-Pub 2018.
19. Willis J, Morelli MP, Morris VK, Loree J, Lam M, Lima Pereira AA, Singh Raghav KP, Kee BK, Sanchez EV, Eng C, Manuel S, Crosby S, Wolff RA, Lanman RB, Talasaz A, Janku F, Overman MJ, Kopetz S. Impact of microsatellite instability (MSI) on tumor clonal evolution in metastatic colorectal cancer (mCRC). J Clin Oncol 36, 2018. e-Pub 2018.
20. Parseghian CM, Loree JM, Morris VK, Lima Pereira AA, Sanchez EV, Kee BK, Singh Raghav KP, Dasari A, Wu J, Raymond VM, Banks K, Talasaz A, Lanman RB, Overman MJ, Kopetz S. Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge. J Clin Oncol 36, 2018. e-Pub 2018.
21. Nusrat M, Oh J, Jiang Z, Dasari A, Fogelman DR, Kee BK, Menter D, Singh Raghav KP, Morris VK, Wu J, Meric-Bernstam F, Morris J, Overman MJ, Kopetz S. Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance. Journal of Clinical Oncology 36, 2018. e-Pub 2018.
22. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Shureiqui I, Kee BK, Wolff RA, Eng C, Menter D, Hamilton SR, Dasari A, Singh Raghav KP, Mehta TR, Manuel S, Kopetz S. Signet ring cell colorectal cancer: Genomic insights into a rare subpopulation of colorectal adenocarcinoma. J Clin Oncol 35, 2017. e-Pub 2017.
23. Tsimberidou AM, Hong DS, Cartwright C, Wheler JJ, Falchook G, Naing A, Fu S, Piha-Paul SA, Janku F, Hwu P, Kee BK, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An Anderson MD precision medicine study. J Clin Oncol 35, 2017. e-Pub 2017.
24. Chun YS, Mehran RJ, Tzeng CD, Kee BK, Dasari A, Sepesi B, Conrad C, Aloia TA, Kopetz S, Vauthey J. LUNA: A randomized phase II trial of liver resection plus chemotherapy or chemotherapy alone in patients with unresectable lung and resectable liver metastases from colorectal adenocarcinoma. J Clin Oncol 35, 2017. e-Pub 2017.
25. Loree JM, Lam M, Morris J, Overman MJ, Singh Raghav KP, Eng C, Dasari A, Kee BK, Fogelman DR, Wolff RA, Jiang Z, Davis JS, Shaw KR, Broaddus R, Routbort M, Luthra R, Maru DM, Menter D, Meric-Bernstam F, Kopetz S. RAS heterogeneity as a prognostic marker in metastatic colorectal cancer. J Clin Oncol 35, 2017. e-Pub 2017.
26. Singh Raghav KP, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Kee BK, Muranyi A, Singh S, Routbort M, Chen K, Shaw KR, Shanmugam K, Maru DM, Fakih M, Kopetz S, Cancer Center TUOTMA, Houston, TX, Systems VM, Inc, Tucson, AZ, Hope CO, Duarte, CA. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J Clin Oncol 34, 2016. e-Pub 2016.
27. Dasari A, Overman MJ, Fogelman DR, Kee BK, Menter D, Singh Raghav KP, Morris VK, Oh J, Wu J, Jiang Z, Tian F, Adam L, Brimer M, Morris J, Meric-Bernstam F, Kopetz S. A phase II and co-clinical study of an AKT inhibitor in patients (pts) with biomarker-enriched, previously treated metastatic colorectal cancer (mCRC). J Clin Oncol 34, 2016. e-Pub 2016.
28. Korphaisarn K, Overman MJ, Fogelman DR, Kee BK, Singh Raghav KP, Shureiqui I, Wolff RA, Patel K, Shaw KR, Eng C, Maru DM, Routbort M, Meric-Bernstam F, Kopetz S, Morris VK, Vilar-Sanchez E, Manuel S, Dasari A. Association of FBXW7 missense mutations (mt) with unfavorable prognosis in metastatic colorectal cancer (mCRC) patients (pts). J Clin Oncol 34, 2016. e-Pub 2016.
29. Clarke C, Korphaisarn K, Jiang Z, Crosby S, Davis DW, Wu W, Singh Raghav KP, Overman MJ, Morris VK, Kee BK, Eng C, Fogelman DR, Navin N, Kopetz S, Cancer Center TUOTMA, Houston, TX, Hospital S, Bangkok, Thailand, Cancer Center TUOTMA, Land S, TX, Inc A, Houston, TX, Inc A, Houston, TX. Antibody-independent isolation and characterization of circulating tumor cells using dielectrophoresis: Fluid flow fractionation in metastatic colorectal cancer. J Clin Oncol 34, 2016. e-Pub 2016.
30. Overman MJ, Kee BK, Fogelman DR, Eng C, Sanchez EV, Shroff RT, Dasari A, Wolff RA, Morris J, Kopetz S. A phaseII Study of nab-paclitaxel in refractory CIMP-high metastatic colorectal cancer. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
31. Morelli M, Overman MJ, Kee BK, Sanchez EV, Morris VK, Fogelman DR, Janku F, Garrett CR, Shureiqi I, Singh Raghav KP, Eng C, Manuel S, Wolff RA, Eltoukhy H, Lanman RB, Talasaz A, Kopetz S. Predictors of clonal evolution in metastatic colorectal cancer patients. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
32. Basen-Engquist K, Parker PA, Eng C, Li Y, Johnson DB, Kee BK, Thomas SS, Wong L, Crocenzi TS, Song J, Fisch M. Randomized trial of a home-based exercise intervention for patients with advanced colorectal cancer: Effects on physical functioning and activity levels. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
33. Morris VK, Morelli M, Janku F, Overman MJ, Kee BK, Fogelman DR, Sanchez EV, Shureiqi I, Garrett CR, Singh Raghav KP, Eng C, Manuel S, Wolff RA, Eltoukhy H, Lanman RB, Talasaz A, Kopetz S. Clinical utility of a circulating cell-free DNA assay for clinical trial enrollment in refractory metastatic colorectal cancer patients. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
34. Hong DS, Morris VK, El Osta BE, Fu S, Overman MJ, Piha-Paul SA, Subbiah V, Kee BK, Tsimberidou AM, Zinner R, Fogelman DR, Bellido J, Shureiqi I, Meric-Bernstam F, Kopetz S. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
35. Huang HJ, Claes B, Falchook GS, Naing A, Piha-Paul SA, Tsimberidou AM, Zinner R, Karp DD, Fu S, Subbiah V, Hong DS, Wheler JJ, Luthra R, Kee BK, Overman MJ, Kim K, Maertens GG, Kurzrock R, Meric-Bernstam F, Janku F. BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics platform (Idylla). J Clin Oncol 32(Suppl), 2014. e-Pub 2014.
36. Morris VK, Overman MJ, Kee BK, Fogelman DR, Eng C, Dasari A, Shroff RT, Deaton L, Manuel S, Garrett CR, Vilar Sanchez E, Pini TM, Shureiqi I, Mills GB, Hamilton SR, Wolff RA, Meric-Bernstam F, Abbruzzese JL, Maru DM, Kopetz S. Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: the ATTACC program experience. J Clin Ocol 32(Suppl 3), 2014. e-Pub 2014.
37. Gomes DBD, Hassabo HM, Al Mutar SS, Shain IH, Rogers J, Nguyen DV, Bolonesi RM, Pini TM, Dasari A, Kopetz S Overman MJ, Eng C, Kee BK, Hassan M, Garrett CR. MD Anderson experience with off-study regorafenib in patients with advanced colorectal cancer. J Clin Oncol 32(Suppl 3), 2014. e-Pub 2014.
38. Lee MS, Overman MJ, Maru DM, Jiang ZQ, Manuel S, Eng C, Kee BK, Fogelman DR, Garrett CR, Advani SM, Vilar Sanchez E, Shureiqi I, Wolff RA, Hamilton SR, Kopetz S. Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer. J Clino Oncol 32(Suppl), 2014. e-Pub 2014.
39. Kopetz, S, Overman MJ, Chen K, Lucio-Eterovic AK, Kee BK, Fogleman DR, Dasari A, Raghav KPS, Vilar Sanchez E, Phillips J, Shureiqi I, Garrett CR, Wolff RA, Patel K, Aldape KD, Luthra R, Routbout M, Maru DM, Meric-Bernstam F, Eng C. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). J Clin Oncol 32(Suppl), 2014. e-Pub 2014.
40. Morelli MP, Overman MJ, Vilar Sanchez E, Morris VK, Shureiqi I, Garrett CR, Fogelman DR, Raghav KPS, Kee BK, Deaton L, Eng C, Wolff RA, Sebisanovic D, Siew LM, Zapanta A, Mei G, Schiller B, Eltoukhy H, Talasaz AA, Kopetz S. Frequency of concurrent gene mutations and copy number alterations in circulating cell-free DNA (cfDNA) from refractory metastic CRC patients. J Clin Oncol 32(Suppl), 2014. e-Pub 2014.
41. Hong DS, Morris VK, Fu S, Overman MJ, Piha-Paul SA, Kee BK, Zinner R, Fogelman DR, Mistry R, Shureiqi I, Meric-Bernstam F, Kopetz S. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. J Clin Oncol 32(Suppl), 2014. e-Pub 2014.
42. Morelli MP, Overman MJ, Dasari A, Kami SMA, Vilar Sanchez E, Eng C, Kee BK, Deaton L, Garrett CR, Diehl F, Angenendt P, Kopetz S. Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR momoclonal antibodies. J Clin Oncol 31(Suppl), 2013. e-Pub 2013.
43. Kee BK, Slack R, Crocenzi TS, Wong L, Esparaz B, Overman MJ, Glover KY, Morris J, Fisch M. A phase II, randomized, double blind comparison of calcium aluminosilicate clay (CASAD) versus placebo (dibasic calcium carbonate) for the prevention of diarrhea in patients (pts) with metastatic colorectal cancer (mCRC) treated with irinotecan (I). J Clin Oncol 31(Suppl), 2013. e-Pub 2013.
44. Subbiah IM, Blackmon SH, Correa AM, Kee BK, Vaporciyan AA, Swisher S, Eng C. Preoperative chemotherapy prior to pulmonary metastatecomy in patients with prior surgically resected primary colorectal carcinoma. J Clin Oncol 30(Suppl n34), 2012. e-Pub 2012.
45. Bhadkamkar NA, Sahin IH, Shen Y, Hassabo HM, Kee BK, Hassan M Garrett CR. Outcomes in patients (pts) with colorectal cancer (CRC) treated with oxaliplatin-based chemotherapy (OC) following prior oxaliplatin exposure. J Clin Oncol 30(Suppl 34), 2012. e-Pub 2012.
46. George B, You Y, Viswanathan, Wen S, Baladandayuthapani V, Overman MJ, Kee BK, Kopetz S, Eng C, Garrett CR. Survival advantage associated with palliative oophorectomy in patietnts with metastatic colorectal cancer (CRC) to the ovaries (mCRC-0): a single institution retrospective analysis. J Clin Oncol 29(Suppl 4), 2011. e-Pub 2011.
47. Hassabo H, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett R. Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-insulin-dependent diabetes (NIDDM). J Clin Oncol 29(Suppl 4), 2011. e-Pub 2011.
48. Arnold SM, Horn J, Eckardt JR, Rinehart JJ, DeSimone P, Fields SZ, Kee BK, Moscow JA, Houchins JC, Leggas M. Clinical and pharmacokinetic (PK) findings in a phase I study of 7-t-butyldimethylsily1-10-hydroxycamptothecin (AR-67) in patients with refractory solid tumors. J Clin Oncol 27:15S, 2009. e-Pub 2009.
49. Leggas M, Horn J, Tsakalozou E, Moscow JA, Fields SZ, Houchins JC, Eckardt JR, DeSimone P, Kee BK, Rinehart JJ, Arnold SM. Pharmacokinetics (PK) of the highly lipophilic and blood stable camptothecin AR-67 (7-t-butyldimethylsily1-10-hydroxycamptothecin) in adult patients with solid malignancies. J Clin Oncol 27:15S, 2009. e-Pub 2009.
50. Higbie V, Shah P, Bent AH, Dasari A, Huey RW, Johnson B, Kee BK, Kopetz S, Lee MS, Ludford K, Morelli MP, Morris VK, Parseghian CM, Singh Raghav KP, YC Shen JP, Willis J, Wolff RA, J Overman AM. Natural history and patterns of progression for dMMR/MSI-H colorectal cancer treated with immune checkpoint blockade: A single center retrospective analysis. 2024 ASCO Gastrointestinal Cancers Symposium.